There is increasing interest in the role that diabetes has in liver-related outcomes in patients with chronic HCV. Elkrief and colleagues have furthered this discussion by indicating that diabetes may be considered a prognostic factor for major liver-related outcomes in patients with chronic HCV infection, including death and transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Elkrief, L. et al. Diabetes mellitus is an independent prognostic factor for major liver related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology http://dx.doi.org/10.1002/hep.27228 (2014).
Stepanova, M., Lam, B., Younossi, Y., Srishord, M. K. & Younossi, Z. M. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J. Viral Hepat. 19, 341–345 (2012).
Younossi, Z. M., Stepanova, M., Nader, F., Younossi, Z. & Elsheikh, E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment. Pharmacol. Ther. 37, 647–652 (2013).
Kiran, Z. et al. Insulin resistance in non-diabetic patients of chronic Hepatitis C. Pak. J. Med. Sci. 29, 201–204 (2013).
Miyajima, I. et al. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: A population-based study in an HCV hyperendemic area. J. Gastroenterol. 48, 93–100 (2013).
Arase, Y. et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49, 739–744 (2009).
Aghemo, A. et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 56, 1681–1687 (2012).
Kawaguchi, Y. & Mizuta, T. Interaction between hepatitis C virus and metabolic factors. World J. Gastroenterol. 20, 2888–2901 (2014).
Moucari, R. et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 59, 1694–1698 (2010).
Sersté, T. et al. Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity. Liver Int. 30, 1131–1136 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Henry, L., Younossi, Z. Chronic HCV infection, diabetes and liver-related outcomes. Nat Rev Gastroenterol Hepatol 11, 520–521 (2014). https://doi.org/10.1038/nrgastro.2014.122
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.122